Gatti M.; Pea F., Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors, «EXPERT REVIEW OF CLINICAL PHARMACOLOGY», 2021, 14, pp. 583 - 599 [articolo]Open Access
Giannella M.; Malosso P.; Scudeller L.; Bussini L.; Rebuffi C.; Gatti M.; Bartoletti M.; Ianniruberto S.; Pancaldi L.; Pascale R.; Tedeschi S.; Viale P.; Paul M., Quality of care indicators in the MAnageMent of BlOOdstream infections caused by Enterobacteriaceae (MAMBOO-E study): state of the art and research agenda, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2021, 57, Article number: 106320, pp. 1 - 9 [articolo]
Meschiari, Marianna; Volpi, Sara; Faltoni, Matteo; Dolci, Giovanni; Orlando, Gabriella; Franceschini, Erica; Menozzi, Marianna; Sarti, Mario; Del Fabro, Giovanni; Fumarola, Benedetta; Guarneri, Francesco; Lanza, Paola; Lorenzotti, Silvia; Saccani, Barbara; Signorini, Liana; Van Hauwermeiren, Evelyn; Gatti, Milo; Pea, Federico; Castelli, Francesco; Mussini, Cristina, Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections, «JAC-ANTIMICROBIAL RESISTANCE», 2021, 3, Article number: dlab188, pp. 1 - 5 [articolo]Open Access
Gatti M.; Andreoni M.; Pea F.; Viale P., Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: A careful appraisal beyond approved indications focusing on unmet clinical needs, «DRUG DESIGN, DEVELOPMENT AND THERAPY», 2021, 15, pp. 3349 - 3378 [articolo]Open Access
Gatti M.; Raschi E.; De Ponti F., Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis, «EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES», 2021, 40, pp. 1169 - 1176 [articolo]Open Access
Gatti M.; Fusaroli M.; Raschi E.; Moretti U.; Poluzzi E.; De Ponti F., Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system, «EXPERT OPINION ON DRUG SAFETY», 2021, 20, pp. 1421 - 1431 [articolo]
Gatti M.; Fusaroli M.; Caraceni P.; Poluzzi E.; De Ponti F.; Raschi E., Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19, «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2021, 87, pp. 1533 - 1540 [articolo]Open Access
Gatti M.; Raschi E.; De Ponti F., Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis, «EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY», 2021, 77, pp. 233 - 239 [articolo]Open Access
Gatti, Milo; Pea, Federico, Should the Clinical Pharmacologist Play a Role in the Multidisciplinary Team Managing Severe Necrotizing Soft-Tissue Infections?, «CLINICAL PHARMACOKINETICS», 2021, 60, pp. 403 - 407 [articolo]
Gaibani, Paolo; Gatti, Milo; Rinaldi, Matteo; Crovara, Cristina; Lazzarotto, Tiziana; Giannella, Maddalena; Lombardo, Donatella; Amadesi, Stefano; Viale, Pierluigi; Pea, Federico; Ambretti, Simone, Suboptimal drug exposure leads selection of different subpopulations of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in a critically ill patient, «INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES», 2021, 113, pp. 213 - 217 [articolo]Open Access
Cojutti P.G.; Rinaldi M.; Gatti M.; Tedeschi S.; Viale P.; Pea F., Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2021, 58, Article number: 106445, pp. 1 - 3 [articolo]
Gatti M.; Giannella M.; Scudeller L.; Viale P., Adaptive trials of new antimicrobials for infections with carbapenem-resistant, Gram-negative bacteria, «THE LANCET INFECTIOUS DISEASES», 2020, 20, pp. 24 - 24 [replica/breve intervento]
Giannella, M.; Bartoletti, M.; Gatti, M.; Viale, P., Advances in the therapy of bacterial bloodstream infections, «CLINICAL MICROBIOLOGY AND INFECTION», 2020, 26, pp. 158 - 167 [articolo]
Gatti M.; Bianchin M.; Raschi E.; De Ponti F., Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review, «EUROPEAN JOURNAL OF INTERNAL MEDICINE», 2020, 75, pp. 60 - 70 [articolo]
Bielli A.; Piazza A.; Cento V.; Comandatore F.; Lepera V.; Gatti M.; Brioschi P.; Vismara C.; Bandi C.; Perno C.F., In vivo acquisition and risk of inter-species spread of blaKPC-3-plasmid from Klebsiella pneumoniae to Serratia marcescens in the lower respiratory tract, «JOURNAL OF MEDICAL MICROBIOLOGY», 2020, 69, pp. 82 - 86 [articolo]
